Slides
Page 1
Q1 FY27 Business Update From archive to architecture Mach7 Technologies Limited | ASX: M7T | 26 October 2026
Page 2
2 Summary of information: This presentation contains general and background information about Mach7 Technologies Limited (“M7T”) activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision. This presentation is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or under any other law. The presentation does not purport to contain all the information that a prospective investor may require in assessing a possible investment in M7T nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). The information provided is in summary form, has not been independently verified, and should not be considered to be comprehensive or complete. It should be read solely in conjunction with the oral briefing provided by M7T and all other documents provided to you by M7T. The information in this presentation remains subject to change without notice. M7T is not responsible for providing updated information and assumes no responsibility to do so. Not financial product advice: This financial information provided in this presentation is for information purposes only. The information contained in this presentation is of a general nature only and is not a financial product, investment advice or a recommendation to acquire M7T securities and has been prepared without taking into account the objectives, financial situation or needs of any person or entity. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. M7T is not licensed to provide financial product advice in respect of its securities or and other financial products. Cooling off rights do not apply to the acquisition of M7T securities. M7T assumes that the recipient is capable of making its own independent assessment, without reliance on this document, of the information and potential investment and will conduct its own investigation. Disclaimer: M7T and its related bodies corporate and each of their respective directors, agents, officers, employees and advisors expressly disclaim, to the maximum extent permitted by the law, all abilities (however, caused, including negligence) in respect of, make no representations regarding, and take no responsibility for, any part of this presentation and make no representation or warranty as to the currency, accuracy, reliability or completeness of any information, statements, opinions, conclusions or representations contained in this presentation. In particular, this presentation does not constitute, and shall not be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of M7T. Future performance: This presentation contains certain forward-looking statements and opinions. The forward- looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements, including projections, forecasts and estimates, are provided as a general guide only and should not be relied on as an indication or guarantee of future performance and involve known and unknown risks, uncertainties and other factors, many of which are outside the control of M7T. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. Risks: An investment in M7T securities is subject to investment and other known and unknown risks, some of which are beyond the control of M7T. You should have regard to the ‘Key Risks’ section of this presentation which outlines some of these risks. Not an offer: This presentation is not, and should not be considered as, an offer or an invitation to acquire securities in M7T or any other financial products and neither this document nor any of its contents will form the basis of any contract or commitment. This presentation is not a prospectus. Offers of securities in M7T will only be made in places which, or to persons to whom it would be lawful to make such offers. This presentation must not be disclosed to any other party and does not carry any right of publication. Neither this presentation nor any of its contents may be reproduced or used for any other purpose without the prior written consent of M7T. No distribution in the US: This presentation is not an offer of securities for sale in the United States. Any securities to be issued by M7T have not been and will not be registered under the US Securities Act of 1933, as amended (the “US Securities Act”) and may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act. No public offer of the securities is being made in the United States and the information contained herein does not constitute an offer of securities for sale in the United States. This presentation is not for distribution directly or indirectly in or into the United States or to US persons. Monetary values: Unless otherwise stated, all dollar values are in Australian dollars (AUD$). The information in this presentation remains subject to change without notice. Sophisticated and professional investor: By attending this presentation, you present and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document as defined in the Corporation Act 2001 (Cth) (“Corporation Act”)) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are in the United States, you are a qualified institutional buyer (as defined under Rule 144A Under the U.S. Securities Act; (iii) if you are outside Australia and the United States, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this presentation and any copies and do not provide this presentation to any other person. No distribution: Distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable security laws. Disclaimer “Forward looking” statements
Page 3
F R O M A R C H I V E T O A R C H I T E C T U R E We complete the patient picture with the patient's pictures. Imaging data, unified, organised, and secure wherever care happens; and integrated with the Electronic Health Record1 under the customer's control. “ From pixel to point of care” 1. An Electronic Health Record (EHR) is a digital version of a patient’s medical history. It is designed to be comprehensive and securely shared with patients and authorised healthcare providers to support coordinated care. It is broader than the Electronic Medical Record (EMR) but often used inter changeably. 3
Page 4
Agenda The reset is producing results. Commercial conversion is catching up. Teri Thomas CEO Shawni Hadfield CFO 01 Results Q1 FY27 financial summary: what the reset is producing 02 The engine Innovation drives our growth: an expanding installed base, targeted new customers, partnerships and Flamingo 03 The horizon Unless otherwise stated, all dollar values are in Australian dollars (AUD) What’s next and what compounds 4
Page 5
Q 1 F Y 2 7 R E S U L T Q1 FY27 result overview Financial highlights for the quarter ended 30 September 2026 0 1 · A C T I O N
Page 6
Q 1 F Y 2 7 F I N A N C I A L R E V I E W 4th consecutive quarter of positive operating cash flowas imaging portfolio advances 2 Revenue quality. ARR run rate up 8.5% in constant currency on pcp1 due to growth in installed base and new customers going live. 3 Receipts. Up 58% on pcp reflecting customer growth and continued focus on disciplined cash collection. 5 Cash generation. Mach7 delivers four consecutive quarters of positive operating cash flow for the first time in its history. Balance sheet. A$19.3M cash and no debt supporting continued investment in product innovation and commercial growth. A leaner, more resilient business, built to scale. 4 1 Payments. 17% lower on pcp demonstrating sustainability of lower cost base following FY26 restructuring. 1. PCP – Prior corresponding period. 6
Page 7
B Y T H E N U M B E R S Q1 FY27 financial summary O P E R A T I N G C A S H F L O W A$0.3M Q1 FY26: −A$3.7M C A R R2 A$25.3M −7.4% on 30 Sep 2025 Constant currency A R R R U N R A T E1 A$23.5M +8.5% on 30 Sep 2025 Constant currency OP E R A T I N G A C T I V I T Y P A Y ME N T S (A$7.0M) −17% on Q1 FY26 R E C E I P T S A$7.3M +58% on Q1 FY26 C LO S I N G C A S H A$19.3M 30 Sep 2025: A$18.9M No debt 1. Annual Recurring Revenue (ARR) Run Rate is subscription and maintenance and support fees at end of Sept, annualised, compared to PCP on a constant currency basis. 2.CARR — Contracted Annual Recurring Revenue, compared to PCP on a constant currency basis. 7
Page 8
0 1 · R E S U L T S The reset is producing results beyond cost reduction Lower costs, faster customer service and growth from existing customers. New customer sales are a focus. Funding growth from operations New customer went live in record time, existing customers are expanding their volumes, and pipeline is growing. Building momentum Positive operating cash flow for the fourth consecutive quarter, with A$19.3M cash and no debt. 8
Page 9
02 The engine Innovation drives our growth: an expanding installed base, targeted new customers, partnerships and Flamingo. 9
Page 10
0 2 · T H E E N G I N E Our steps to growth, in order of speed to revenue 1. Protect and expand the installed base Existing customer volume growth and cross-selling is the fastest revenue available to us. 2. Win new customers Targeting well-aligned prospects with products we deliver today, helped by a clear roadmap and visible progress to a growing customer reference base. 3. Flamingo is easier to adopt Modules added to the platform customers already run, with a lower-cost infrastructure option, and differentiators to drive new sales. Easier purchasing and deployment due to modularity reduces sales friction. 4. EMR1 integration and advisory work Early development paths that create more ways to grow the pipeline, get market exposure, and make it easier for customers to buy while also supporting growth in revenue. 1. An Electronic Medical Record (EMR) is a digital patient record, a subset of the EHR. 10
Page 11
0 2 · T H E E N G I N E Increasedpace and volume of development on a lower cost base 2.5x Q1 FY27 capitalised development vs pcp Deeper customer engagement directly drives development. I M A G I N G D A T A A R C H I T E C T U R E VNA and Flamingo One architecture. Flamingo modernises the VNA holding customers’ images and adds more. E N T E R P R I S E D I A G N O S T I C V I E W I N G eUnity Enterprise Viewer Modernising and growing the product customers love. E X E C U T I O N Improved release process Faster, fuller, more communication. 4.4x AI-enabled productivity gain 11
Page 12
0 2 · T H E E N G I N E Flamingo Our innovative next-generation architecture: containerised deployment, a modern database, one unified experience, and new capabilities sold as modules on top. Will be shown at RSNA (Radiological Society of North America) 2026, the industry's largest imaging meeting, held from 29 Nov to 3 Dec. Foundation One modern core, included with the first module a customer buys, including DICOM, HL7, FHIR and other APIs. Storage On-premise, cloud and hybrid, with imaging lifecycle management. Worklist A flexible and modern workspace used across complex sites Sonar Our imaging platform's health: native observability and IT Operations Management (ITOM) Flow Our next evolution in intelligent routing and workflow automation. The right image finds the right place, automatically. 12
Page 13
0 2 · T H E E N G I N E Why customers want Flamingo Each module saves money, time or risk on the images and systems customers already have. Save money Buy only what you need Start with one module and add more later. Customers can buy orchestration without the full VNA, which is how our first new customer started last year . Save time One worklist across every site All types of users can read from a single list in the eUnity viewer they already use, with less switching between systems. Lower risk and cost See problems early, on one screen Sonar builds in monitoring and performance tracking, replacing third-party monitoring tools customers pay for today. Less manual work The right image, in the right place Flow routes images automatically using each customer’s rules, so staff spend less time moving studies by hand. Shaped with customers: worklist feedback sessions held, and Sonar has an early adopter and a development partner. 13
Page 14
03 The horizon 14
Page 15
0 3 · T H E H O R I Z O N From reset to the imaging data layer The reset is largely behind us and we are building the growth engine this year. The last two phases reflect the company we are building. N O W Prove the growth engine Grow and win customers with today’s products. Release new Flamingo products to early adopters. Raise our profile with a new website, branding, outreach and industry expert engagement. Maintain discipline to keep revenue growing faster than costs. N E X T Compound and lead Flamingo modules sold across the base, to net new directly, and through partners, with Sonar monitoring, more image types and more Flamingo modules. Each module a customer adds makes the next easier to buy, sets us apart, and lowers barriers to new sales. A M B I T I O N Own the imaging data layer Imaging is about 90% of healthcare data¹, and most of its growth is outside radiology. As AI uses more of it, from pathology to video triage, it needs one organised, governed source. We intend to be that source. ¹ Towbin, A. (2026, May 21). Imaging accounts for roughly 90% of healthcare data. HealthSystemCIO. 15
Page 16
Contact Us Investor Relations, Mach7 Françoise Debelak Dixon +61 (0) 412 292 977 ir@mach7t.com Registered Office: Suite 2, Level 11, 385 Bourke St, Melbourne, VIC 3000 Mach7 Technologies Limited This document was authorised for release to the ASX by Teri Thomas, Managing Director and Chief Executive Officer